A detailed history of Northern Trust Corp transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Northern Trust Corp holds 15,750 shares of PRQR stock, worth $42,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,750
Previous 15,932 1.14%
Holding current value
$42,052
Previous $26,000 7.69%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.64 - $2.24 $298 - $407
-182 Reduced 1.14%
15,750 $28,000
Q2 2024

Aug 14, 2024

SELL
$1.65 - $2.39 $2,455 - $3,556
-1,488 Reduced 8.54%
15,932 $26,000
Q2 2023

Aug 11, 2023

BUY
$1.62 - $2.32 $9,998 - $14,319
6,172 Added 54.87%
17,420 $28,000
Q1 2023

May 15, 2023

BUY
$1.99 - $3.66 $22,383 - $41,167
11,248 New
11,248 $23,000
Q1 2022

May 13, 2022

SELL
$0.9 - $8.39 $5,697 - $53,108
-6,330 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$6.58 - $8.44 $41,651 - $53,425
6,330 New
6,330 $51,000
Q3 2021

Nov 15, 2021

SELL
$5.16 - $8.47 $69,561 - $114,184
-13,481 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$5.75 - $7.59 $25,484 - $33,638
-4,432 Reduced 24.74%
13,481 $91,000
Q1 2021

May 12, 2021

BUY
$4.14 - $9.22 $74,159 - $165,157
17,913 New
17,913 $118,000
Q4 2019

Feb 14, 2020

SELL
$5.84 - $10.51 $226,253 - $407,178
-38,742 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$9.1 - $15.55 $39,539 - $67,564
4,345 Added 12.63%
38,742 $353,000
Q1 2019

May 13, 2019

SELL
$12.5 - $18.48 $97,500 - $144,144
-7,800 Reduced 18.48%
34,397 $477,000
Q4 2018

Feb 12, 2019

BUY
$15.25 - $22.4 $643,504 - $945,212
42,197 New
42,197 $666,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $191M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.